Summary & Overview
HCPCS J9035: Injection, bevacizumab, 10 mg
HCPCS Level II code J9035 denotes a 10 mg unit of bevacizumab administered by injection. Bevacizumab is a monoclonal antibody used in oncology and certain ophthalmologic indications; accurate coding of drug units affects reimbursement, inventory tracking, and clinical documentation. Nationally, consistent use of J9035 supports standardized reporting of biologic oncology therapies and aligns billing for high-cost infused medications.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication reviews payer coverage frameworks, unit-based billing practices, and common billing modifiers and reporting conventions that affect payment and claim adjudication for injectable biologics.
Readers will find benchmarks for unit reporting and reimbursement patterns, policy updates that influence billing for infused biologics, and clinical context relevant to infusion and outpatient administration. Sections include coding guidance for unitization, payer coverage considerations, and operational issues for infusion centers and outpatient clinics. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9035 represents Injection, bevacizumab, 10 mg. This code describes the drug product bevacizumab administered by injection, reported in 10 mg units.
Service type: Injectable oncologic/ophthalmologic biologic therapy
Typical site of service: Infusion center or outpatient clinic, with potential use in ambulatory surgical settings depending on clinical context.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a solid tumor (for example, metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, or renal cell carcinoma) who is receiving intravenous cancer-directed therapy including bevacizumab. The service described by J9035 (bevacizumab 10 mg) is administered in an outpatient infusion center, oncology clinic, or hospital outpatient department. The clinical workflow includes prescription and chemotherapy order verification by the oncologist, pharmacy compounding of the weight‑based dose into an IV infusion bag, pre‑infusion nursing assessment and baseline vital signs, infusion via peripheral IV or central venous access over the recommended infusion time, monitoring for acute infusion reactions (hypertension, hemorrhage, thromboembolism, proteinuria, wound healing complications), documentation of lot number and vial usage, and post‑infusion disposition and scheduling of subsequent cycles. Typical documentation elements include diagnosis, weight and calculated dose, number of vials used (units of J9035), infusion start and stop times, pre‑ and post‑vital signs, adverse reaction notes, and the administering clinician and provider taxonomy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JZ | Not billed to Medicare Part B (not applicable) |